Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumab

Conclusion: Hematopoietic abnormalities are common during natalizumab treatment. Given the lack of consequences of this finding during long-term follow-up, it is generally justifiable to refrain from further diagnostic procedures when observing hematopoietic abnormalities in patients using natalizumab.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research